Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 30;55(4):175–180. doi: 10.5483/BMBRep.2022.55.4.137

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 by the The Korean Society for Biochemistry and Molecular Biology

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 4 — Effects of AaLS-PP on neovascularization in ischemic hindlimbs. Staining capillaries and blood vessels in ischemic limbs 28 days after intramuscular injection of PBS, PP, AaLS, or AaLS-PP. (A) Representative images immunostained with CD31 (green) or α-SMA (red). Nuclei (blue) were counterstained with DAPI. Overlaid images are shown. (B) Quantitative analysis of capillary density expressed by the number of CD31-positive capillaries per high power field (HPF). (C) Quantitative analysis of α-SMA-positive vessels per HPF. Data are presented as mean ± S.D. (n = 24). *P < 0.05 vs. PBS.